Retatrutide is currently in Phase 3 clinical trials, which are the large-scale studies required to confirm efficacy and safety before regulatory submission
Today, I want to walk you through one of the most effective, evidence-based strategies we have for combating menopause-related visceral fat: the combination of GLP-1 medications and hormone therapy
It is not approved anywhere in the world as of 2025
Compounded GLP-1s: A More Accessible Pathway
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations and gave upbeat guidance for 2025
Seek prompt medical review if you experience persistent vomiting, signs of dehydration, inability to maintain adequate oral intake, or symptoms such as unusual fatigue, muscle weakness, numbness or tingling, which may indicate nutritional deficiencies requiring investigation